By the Top Tier Newswire AI Desk · October 1, 2026 at 3:51 PM ET · reviewed against 32 wire stories
LIQUIDIA CORP (LQDA) is down -8.00% in the latest session. Our newswire has captured 32 stories on LQDA across 10 sources in the last 36 hours, with AI sentiment reading bearish (avg 42/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
LQDA stock closed down 8.00% at $27.84 on October 1, 2026, marking a sharp decline driven by a federal court ruling that found Liquidia infringing on two claims of United Therapeutics’ U.S. Patent No. 11,826,327. The ruling, issued by U.S. District Judge Richard G. Andrews in the District of Delaware, invalidated Liquidia’s arguments and cast uncertainty over its Yutrepia product, a key part of its commercial strategy. The decision also triggered several analyst downgrades and a sharp intraday selloff.
What Happened
The court ruled that Liquidia induces infringement of two claims related to inhaled treprostinil dosing for pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics said the ruling rejected Liquidia’s invalidity arguments and affirmed the validity and infringement of the claims. Liquidia stated the remaining asserted claims were found invalid, but the partial loss still raised concerns about its ability to commercialize Yutrepia without legal constraints. The ruling led to immediate market action: Liquidia’s stock opened with a 3.2% gap down and fell further to a session low of $22.31 before settling at $27.82. Analysts at BTIG and Raymond James downgraded the stock to Neutral and Outperform, respectively, citing the ruling as a significant headwind.
What The Data Shows
The intraday session saw 16.8 million shares traded, more than nine times the 3-month average, as the stock declined from $29.30 to $27.82. The 52-week range for LQDA is $21.35 to $93.61, and the stock has fallen 62.7% over the past eight sessions. Recent insider transactions show 20 sales totaling $56.9 million in the last 90 days, with the most recent filing on September 15. The unusual options activity included a notable call print of $368,000, indicating speculative positioning. The 52-week tape also showed two fresh 52-week lows on the same day as the ruling.
What To Watch
Liquidia has no scheduled earnings date in the near term, but investors will be watching for further analyst coverage and potential appeals of the patent ruling. The stock remains highly sensitive to legal developments and regulatory outcomes.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LQDA · Oct 1 session (5-min) · -7.96% vs prior close · updated 8:52 PM ETAI sentiment, last 36h · averaged over 32 stories · 42/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
49d agoStocktwits NewsBEARISH 28General
LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path
U.S. District Judge Richard G. Andrews of the District of Delaware found on Wednesday that Liquidia induces infringement of claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327.
50d agoThe FlyBEARISH 34General
Liquidia falls -14.6%
50d agoSeeking AlphaBEARISH 38Analyst
Liquidia cut to Neutral at BTIG after patent win for United Therapeutics
Liquidia (LQDA) stock slides as BTIG downgrades the company after a patent ruling that favored its rival United Therapeutics (UTHR). Read more here.
50d agoMarketChameleonBULLISH 63General
UTHR jumps after court finds Liquidia infringed two claims tied to inhaled treprostinil for PH-ILD
October 1, 2026
United Therapeutics said a Delaware federal court found Liquidia infringed two claims of UTHR’s ’327 patent tied to inhaled treprostinil dosing for PH-ILD and rejected Liquidia’s invalidity arguments. UTHR stated it believes it is entitled to seek an order directing FDA to withdraw Yutrepia’s NDA approval until labeling omits PH-ILD, and it also intends to pursue monetary damages for past infringement.
50d agoThe FlyBEARISH 35General
Liquidia falls -15.7%
50d agoThe FlyNEUTRAL 48Analyst
Liquidia downgraded to Outperform from Strong Buy at Raymond James
50d agoMarketChameleonBEARISH 38General
Liquidia Faces Partial '327 Patent Loss as Court Finds Two Claims Valid and Infringed
October 1, 2026
Liquidia said a U.S. District Court ruled that two asserted claims of United Therapeutics’ ’327 patent are valid and infringed by YUTREPIA, while the remaining asserted claims were found invalid. The parties must submit a proposed form of judgment and remedy within one week, as Liquidia signals potential appeals and reiterates its plan to seek an FDA label change removing PH-ILD.
50d agoThe FlyNEUTRAL 50Analyst
Liquidia downgraded to Neutral from Buy at BTIG
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →